Claim That EDTA Suppositories Remove Mercury -- Possibly True?
Dr. Carlos Viana -- Aruba -- Possible Source Of False Data on EDTA Chelation
Michael L. Culbert -- Connected With Research on EDTA Suppositories
How To Detoxify Mercury -- DMPS & DMSA
International Council For Health Freedom
Newsletter -- Winter 2001/Spring 2002 Vol. V, Nos. 3-4
On the first page, headline: "EDTA Chelation Therapy breakthrough -- An Exclusive Report"
Also, headline: "CCS 'humanitarian' award to Culbert"
Suppository EDTA 'changing field of chelation'
USA -- The suppository form of the chelating agent EDTA beats the intravenous approach heads-down in removing mercury from the body, according to an Aruba physician who is one of a growing number of medical professionals utilizing the rectal-insertion product which, in the words of another satisfied clinician, "has changed teh field of chelation therapy."
In the meantime, evidence is growing that EDTA -- for years the centerpiece of a major controversy in cardiovascular/circulatory therapy -- has an even broader spectrum of utility than known earlier, including its use as an antiretroviral agent and hence useful against AIDS.
In information made available exclusively to the ICHF Newsletter, Salt Lake City-based World Health Products relayed an October 3 letter from Dr. Carols Viana, Viana Natural Healing Center, Aruba, finding that the company's suppository product -- Detoxamin -- has clear benefits over slow-drip intravenous EDTA in rapidly detoxifying the body of mercury.
The work by Dr. Viana, an Oriental Medical Doctor and nutritionist, is of considerable significance since information continues to link mercury -- from a host of both industrial and medical sources -- to a wide array of physiological ills in humans (see companion stories).
The launching by World Health Products of a safe and convenient form of EDTA (the synthetic amino acid ethylene-diamine-tetracetic acid) is a dramatic follow-up to an earlier attempt (in 1999) to market a rectal product which, while securing a number of extremely promising results by doctors in the US, Mexico and the Philippines (see ICHF Newsletter III: 3-4, 1999 and IV: 1, 2000) had pr9oblems both with insertion and local side effects.
"But those problems have been solved and we now have an EDTA delivery system getting dramatic results and without any side effects" said a spokesman for World Health Products (WHP) which now has world exclusivity for the suppository.
WHP has made available several case studies from Great Smokies Medical Center, Asheville, NC, which has been using the product for several months, and from osteopath Erik Von Kiel, Pennsylvania.
According to Dr. Von Keil:
"DeToxamin has changed the field of chelation therapy.
"Rectal suppository EDTA broadens the field of EDTA chelation patients in every way. No patients unable to come to the office regularly, patients with more advanced renal disease and patients unable or unwilling to tolerate intravenous application of EDTA are able to obtain chelation with as good or better results than the present IV method.
"Safer, cheaper, more cost effective, less invasive, and still more effective. What more is there to say? This changes the field of chelation therapy."
It also widens the fissure among chelation doctors, the majority of whom still use liquid intravenous EDTA slow-dripped daily over several hours for many days at a highly useful alternative to coronary bypasses, balloon angioplasties, beta-blocker, calcium-channel and other drugs, and doctors who are promoting the use of "oral chelation."
Since its research inception in the last century, EDTA has been a major controversy -- if only because it posed a major economic challenge to the surgical and drug-based approaches to orthodox heart circulatory disease (see the "Heart Hustle" chapter in M. L. Culbert's Medical Armageddon).
Over the years, EDTA chelation therapy has proven itself in heart-circulatory disorders and is the extension, particularly when in the hands of a metabolically oriented physician, it was accompanied by proper diet and exercise.
In 1999/2000 Arizona biochemist Dr. Ronald Bennett strongly supported at the research and theoretical levels by California's Bruce Halstead, MD, a widely recognized world pioneer in EDTA, among other things, introduced an earlier version of an EDTA suppository.
Both in anecdotal cases in the US as well as in the Philippines the suppositories were shown to have the same benefit of IV EDTA chelation but without the inconvenience factor of lengthy clinic visits.
In a limited study in Mexico of 10 HIV/AIDS patients, striking results in immune improvements were seen -- a follow-up, the researchers said, to an East German study in a982 (Wunderlich and Sydow) demonstrating EDTA's effectiveness in distinguishing the membranes of "type B" retroviruses, which include HIV.
In 1998, a study of 20 children in the Dominican Republic demonstrated their suppository EDTA "very effectively removes lead from children with lead poisoning, even reflecting a higher conversion among after 10 days without treatment."
A report to WHP from John L. William Jr., MD and Eileen M. Wright, MD of Great Smokies Medical Center stated that although the physicians "are looking forward to reporting pending pre-and post-ultraFast CT scan of the heart as objective measurement of treatment with Detoxamin after a few months of treatment, some of th early responses, sometimes as early as within the first few days of treatment, have been encouraging. Here are a few promising examples of GSMC patients:
"Edith a 79-year-old woman with a history of a 5-vessel coronary artery bypass graft 20 years to, is understandably reluctant to undergo another bypass . . . She complained of chest pain only partially relieved by the 10 or more nitroglycerine tablets she was taking each day, with hourly dosing of 1 or 2 nitro tabs hourly during the night.
"Edith had received over 100 IV EDTA chelation treatments over a period of several years. Repeat coronary angioplasty in 2001 revealed obstructed grafts, but native coronary arteries were unobstructed. Edith's cardiologist offered her medical or surgical intervention. She refused bypass surgery.
"Edith was started as a Detoxamin EDTA suppository each evening at bedtime, with tetracycline 500 mg by mouth. She experienced a pain-free night after her first dose. As seven weeks of nightly treatment have elapsed, Edith now reports a greatly reduced incidence of angina -- three mild episodes last week.
"Dr. Wright and Wilson report that it is typical to have patients, even after a few doses, comment, "it could be my imagination, but I think I'm feeling better.'
"Another patient of CSMC, Larry, is a 62-year-old man with Menien's Disease who experienced a self-reported 50 percent improvement with debilitating vertigo after thirty EDTA IVs. After one month of Detoximan suppositories he reports an additional 30 percent improvement with the vertigo.
"The wife of Steven, a 70-year-old man with a diagnosis of Reker's Syndrome, came with her husband to GSMC for a follow-up visit after one month of Detoxamin and tetracycline stating, "he's a different man!' Exams showed increased grip strength and tolerance of exercise and decreased pain in the point of doing yard work and resuming projects around the house."
On Oct. 2, Joe H. Ferguson of American Fork, UT, wrote: "I am 70 years old. I have been taking Detoxamin since the 8th of August (that's 7 weeks and 5 days) and I am feeling GREAT!
"Before, I suffered from a lack of energy -- bordering on chronic fatigue syndrome. Now, I am riding my bicycle regularly, playing tennis and jumping on the trampoline. I feel better than I have in 20 years. It must be because Detoxamin is removing the plaque from my circulatory system so that my blood can nourish my body better. My weight has dropped from 240 to 230 (in slightly under 8 weeks) because I have more energy to exercise."
(Detoxamin is a patented form of 750 mg of EDTA in suppository form. World Health Products also provides Detoxamin Adrenal Supplements and Immune Defense Supplements to accompany suppository use and to replace the useful nutrients which may be removed during chelation therapy. These products are available only to medical professionals. For the doctor-patient referral service, please contact World Health Products at 1 877 655-4553).
The Mercury Detox Results From Aruba
Aruba -- Dr. Carlos Viana, OMD, Viana Natural Healing Center, Kibaima, Aruba, on Oct. 3 sent the following letter to World Health Products:
We purchased Detoxamin to try on our patients. As a member of The International Academy of Oral Medicine and Toxicology, we are always looking for safer methods to detoxify heavy metals. Many physicians do not realize that EDTA is a method for reducing somatic mercury. Many physicians are looking at the heavy metals excreted by the kidneys through EDTA IV chelation and do not find mercury being excreted in the urine. These physicians then wrongly assume that EDTA is not a good chelator of mercury. In fact, EDTA has a greater affinity for mercury than copper, lead, zinc, in that order.
The excretion route of mercury is though the large intestine. Traditionally, to detoxify mercury many physicians will use DMSA because it is an oral drug. Therefore, it was logical to look for the mercury in feces because that drug was working through the gastrointestinal (G.I.) tract. Very few physicians were looking at chelated heavy metals in feces with a drug that works through the blood/kidney/urine route.
Second, of the physicians that did look for mercury in their patients' feces and did not find much excreted mercury, it is probably because they did not check the third bowel movement. After IV EDTA treatment mercury will not present after the next bowel movement, but will present after the third bowel movement.
At our clinic we are finding benefits with Detoxamin suppositories over IV EDTA in removing mercury.
1.) Because mercury is going to be found in the large intestines normally, EDTA suppositories will chelate the mercury in the large intestine first.
2.) The EDTA that travels into the blood stream and binds with lead will be excreted through the kidney/urine and EDTA that bines with mercury in the body will travel back to the rectum where it will bind more securely with EDTA that has not crossed into blood.
3.) With Detoxamin we do not have to wait for the third bowel movement!
The next day's bowel movement already has a mercury burden.
We are very impressed with initial clinic trials of Detoxamin suppositories and are looking forward to extending our chelation use. Please feel free to quote our letter.
[Karl Note: The following web page identifies a Dr. Viana from Aruba, as an acupuncturist.]
 |
 |
 |
|
| Specialists |
| Oriental Medical Doctor - Acupuncturist |
|
Name: |
Address: |
Telephone #: |
Fax #: |
|
Dr. Carlos Viana |
Kibaima
7 |
851270 |
854789 |
|
Mieke
Chin |
Savaneta 530 |
841660 |
|
|
|
[Karl Note: Dr. Viana is publicly listed as NOT being a member of this diving group. One could presume that he has claimed to be, and is hereby publicly revealed as not being a member. Source.]
| In the Quality Assurance Report, PADI publishes quality assurance activities within the last year. The intent of this feature is to publicize the name of individuals who have been suspended or expelled from PADI membership. The following information reflects the worldwide membership. For a listing of past reports please see our archives page. |
Dr. Carlos Viana of Aruba is not a PADI Member